Is there a physiological role for gonadotrophin oligosaccharide heterogeneity in humans? III. Luteinizing hormone heterogeneity: A medical physiologist's perspective

Human Reproduction

Volumn 16, Issue 6, 2001, Pages 1058-1064

  Bergendah, M ^a   Veldhuis, J D ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Bioassays; Hormone physiology; LH isoforms; Oligosaccharide heterogeneity

Indexed keywords

ANTIANDROGEN; ESTROGEN; GONADORELIN; GONADOTROPIN; LUTEINIZING HORMONE; OLIGOSACCHARIDE; OPIATE ANTAGONIST; TAMOXIFEN;

GAMETOGENESIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GROWTH; HORMONE ACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; KINETICS; MENSTRUAL IRREGULARITY; METABOLIC PARAMETERS; NONHUMAN; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PUBERTY; REVIEW; SEXUAL MATURATION; STEROIDOGENESIS; SUBFERTILITY; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL;

EID: 0034975256     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.6.1058     Document Type: Review

References (100)

1. Serum luteinizing hormone concentrations increase 100-fold in females from 7 years of age to adulthood, as measured by time-resolved immunofluorometric assay
2. Carbohydrate-specific receptors of the liver
3. Pituitary glycoprotein hormone oligosaccharides: Structure, synthesis, function of the asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin
4. Both of the beta-subunit carbohydrate residues of follicle-stimulating hormone determine the metabolic clearance rate and in-vivo potency
5. Comparisons of pituitary: Serum luteinizing hormone (LH) ratios in the castrated rat by radioimmunoassay and OAAD bioassay
6. In vivo bioactivities and clearance patterns of highly purified luteinizing hormone isoforms
7. Polycystic ovary syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbility in women
8. Biological to immunological ratios: Reevaluation of a concept
9. Characterization and biological properties of chemically deglycosylated human chorionic gonadotrophin
10. Analysis of the ratio of biological to immunological LH secreted during the oestrogen-induced LH surge in the ewe
11. Comparison of pulsatile luteinizing hormone secretion between prepubertal children and young adults: Evidence for a mass/amplitude-dependent difference without gender or day/night contrasts
12. Sustained inhibitory actions of a potent antagonist of gonadotrophin-releasing hormone in postmenopausal women
13. Monoclonal antibodies to lutropin: Are our immunoassays too specific?
14. Preponderance of basic isoforms of serum luteinizing hormone (LH) is associated with the high bio/immuno ratio of LH in healthy women and women with polycystic ovarian disease
15. Pathophysiological relationships between the biological and immunological activities of luteinizing hormone
16. Effects of luteinizing hormone releasing hormone (LHRH) upon bioactive and immunoreactive serum LH levels in normal subjects
17. In vitro bioassay of LH in human serum: The rat interstitial cell testosterone (RICT) assay
18. Bioassay of circulating luteinizing hormone in the Rhesus monkey: Comparison with radioimmunoassay during physiological changes
19. Mode of secretion of bioactive luteinizing hormone in man
20. Contemporary aspects of discrete peak detection algorithms. II. The paradigm of the luteinizing hormone pulse signal in women
21. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease
22. The significance of a single serum LH measurement in women with cycle disturbances: Discrepancies between immunoreactive and bioactive hormone estimates
23. A hepatic reticuloendothelial cell receptor specific for SO4-4GaINAcbeta1, 4GIcNAcbeta1,2Manalpha that mediates rapid clearance of lutropin
24. Identification of two point mutations in the gene coding luteinizing hormone (LH) beta-subunit, associated with immunologically anomalous LH variants
25. LH measurements by in vitro bioassay and a highly sensitive immunofluorometric assay improve the distinction between boys with constitutional delay of puberty and hypogonadotropic hypogonadism
26. Polymorphism of gonadotrophin action; Molecular mechanisms and clinical implications
27. The bio/immune ratio of plasma luteinizing hormone does not change during the endogenous secretion pulse: Reanalysis of the concept using improved immunometric techniques
28. Sensitive immunoassay and in vitro bioassay demonstrate constant bioactive/immunoreactive ratio of luteinizing hormone in healthy boys during the pubertal maturation
29. Mutations and polymorphisms in gonadotrophin genes
30. Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays
31. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotrophin secretion: Reevaluation by a highly sensitive immunometric assay
32. Inherited disorders of the gonadotrophin hormones
33. Luminescence luteinizing hormone/choriogonadotrophin (LH/CG) bioassay: Measurement of serum bioactive LH/CG during early pregnancy in human and macaque
34. A common polymorphic allele of the human luteinizing hormone beta-subunit gene: Additional mutations and differential function of the promoter sequence
35. Serum bioactive luteinizing and follicle-stimulating hormone concentrations in girls increase during puberty
36. Serum bioactive gonadotrophins during male puberty: A longitudinal study
37. Abrogation by a potent GnRH antagonist of the estrogen/progesterone-stimulated surge-like release of LH and FSH in postmenopausal women
38. Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome
39. The control of bioactive luteinizing hormone secretion in women with polycystic ovary syndrome
40. Reduction of the potency of luteinizing hormone by estrogen
41. Bioactive LH: A test to discriminate precocious puberty from premature thelarche and adrenarche
42. LH bioactivity increases more than immunoreactivity during puberty
43. Decrease in luteinizing hormone biological activity/immunoreactivity ratio in elderly men
44. Pulsatile pituitary gonadotrophin secretion during maturation of the dominant follicle in monkeys: Estrogen positive feedback enhances the biological activity of luteinizing hormone
45. Effects of oestrogen treatment on serum gonadotrophin bioactivity, immunoreactivity and isohormone distribution, and on immunoreactive inhibin levels in prostatic cancer patients
46. Less acidic forms of luteinizing hormone are associated with lower testosterone secretion in men on haemodialysis treatment
47. Age-related changes in the pituitary-testicular axis in normal men; Lower serum testosterone results from decreased bioactive LH drive
48. Increased bioactive luteinizing hormone levels and bio/immuno ratio in women with hyperthecosis of the ovaries: Possible role of hyperinsulinemia
49. Persistence of concordant LH, testosterone and alpha subunit pulses following LHRH antagonist administration in normal men
50. Individual differences in lutropin immunoreactivity revealed by monoclonal antibodies
51. An immunologically anomalous luteinizing hormone variant in a healthy woman
52. Serum gonadotrophin isoforms become more basic after an exogenous challenge of gonadotrophin-releasing hormone in children undergoing pubertal development
53. Changes in the isoforms of luteinizing hormone and follicle-stimulating hormone during puberty in normal children
54. The role of luteinizing hormone-beta gene polymorphism in the onset and progression of puberty in healthy boys
55. Biologically active luteinizing hormone (LH) in plasma. III. Validation of the in vitro bioassay when applied to male plasma and the possible role of steroidal precursors
56. Prevalence of an immunological LH beta-subunit variant in a UK population of healthy women and women with polycystic ovary syndrome
57. Association of molecular variants of luteinizing hormone with male infertility
58. Microheterogeneity of LH in pituitary glands from women of pre and post-menopausal age
59. Bioactive and immunoreactive serum LH in normal prepubertal and pubertal boys
60. Bioassayable luteinizing hormone during childhood and adolescence and in patients with delayed pubertal development
61. Pulsatile release of bioactive LH in prepubertal girls: Discordance with immunoreactive LH pulses
62. Biologically active luteinizing hormone (LH) in plasma. V. A re-analysis of the differences in the ration of biological to immunological LH activities during the menstrual cycle
63. A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both both basal and pulsatile LH in adolescents with polycystic ovarian syndrome
64. Effect of desialylation of human chorionic gonadotrophin on its metabolic clearance rate in humans
65. Inhibition of hormone-induced cyclic AMP production and steroidogenesis in interstitial cells by deglycosylated lutropin
66. Gonadotropin-releasing hormone action upon luteinizing hormone bioactivity in pituitary gland: Role of sulfation
67. Pulsatile immunoreactive and bioactive luteinizing hormone secretion in adolescents with chronic renal failure
68. Immunoreactive and bioactive luteinizing-hormone in pubertal patients with chronic-renal-failure
69. The sialylated oligosaccharides of recombinant bovine lutropin modulate hormone bioactivity
70. Bio- and immunoactive luteinizing hormone responses to low doses of gonadotrophin-releasing hormone (GnRH): Dose-response curves in GnRH-deficient men
71. Screening of the mutations in luteinizing hormone beta-subunit in patients with menstrual disorders
72. Biological and immunological characterization of human luteinizing hormone discharged in a pulsatile fashion in the normal menstrual cycle
73. Pulsatile bioactive luteinizing hormone secretion in men with chronic renal failure and following renal transplantation
74. A new contributing factor to polycystic ovary syndrome: The genetic variant of luteinizing hormone
75. Testosterone reduces the bioactivity of luteinizing hormone (LH) in man
76. Ovarian binding of intact and desialylated hCG in vivo and in vitro
77. Biological properties of hCG after removal of terminal sialic acid and galactose residues
78. Attenuated release of biologically active luteinizing hormone in healthy aging men
79. Increased potency and sustained suppressive actions of a new gonadotrophin-releasing hormone (GnRH) antagonist peptide in man
80. Contemporary aspects of discrete peak detection algorithms. I. The paradigm of the luteinizing hormone pulse signal in men
81. Suppressive actions of a gonadotrophin-releasing hormone (GnRH) antagonist on LH, FSH, and prolactin release in estrogen-deficient postmenopausal women
82. Estrogen regulates the gonadotrophin-releasing-hormone stimulated secretion of biologically active luteinizing hormone in man
83. Luteinizing hormone and different genetic variants, as indicators of frailty in healthy elderly men
84. Steroidal regulation of biologically active luteinizing hormone secretion in men and women
85. Biologically active luteinizing hormone is secreted in episodic pulsations that vary in relation to stage of the menstrual cycle
86. The pituitary gland secretes in bursts: Appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations
87. Preferential release of bioactive luteinizing hormone in response to endogenous and low-dose exogenous gonadotrophin releasing hormone (GnRH) pulses in man
88. Physiological attributes of endogenous bioactive luteinizing hormone secretory bursts in man: Assessment by deconvolution analysis and in vitro bioassay of LH
89. Pathophysiological features of the pulsatile secretion of biologically active luteinizing hormone in man
90. Evidence that androgen negative-feedback regulates hypothalamic GnRH impulse strength and the burst-like secretion of biologically active luteinizing hormone in men
91. Differential responses of biologically active LH secretion in older versus young men to interruption of androgen negative feedback
92. Effects of aging and illness on the pituitary testicular axis in men: Qualitative as well as quantitative changes in luteinizing hormone
93. Metabolic clearance rates of the subunits of human chorionic gonadotrophin in man
94. Polymorphism of human pituitary lutropin (LH) isolation and partial characterisation of seven isohormones
95. Hypogonadism caused by a single amino acid substitution in the beta-subunit of luteinizing hormone
96. Median charge and charge heterogeneity of human pituitary FSH, LH and TSH. II. Relationship to age and sex
97. More basic forms of both human follicle-stimulating hormone and luteinizing hormone in serum at midcycle compared with the follicular or luteal phase
98. 17 Beta-oestradiol counteracts the formation of the more acidic isoforms of follicle-stimulating hormone and luteinizing hormone after menopause
99. Time-related effects of a progestogen on the isoforms of serum gonadotrophins in 17 beta-oestradiol treated post-menopausal women
100. Patterns of pulsatile luteinizing hormone secretion from childhood to adulthood in the human male: A study using deconvolution analysis and an ultrasensitive immunofluorometric assay